Form 4: Akero Therapeutics COO Jonathan Young Sells Shares Under 10b5-1 Trading Plan

Akero Therapeutics' Chief Operating Officer, Jonathan Young, executed sales of common stock on April 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jonathan Young, the Chief Operating Officer of Akero Therapeutics, sold 4,600 shares of common stock at a weighted average price of $24.3267 on April 1, 2024.
• An additional 400 shares were sold at a weighted average price of $25.025 on the same day.
• These transactions were executed under a pre-existing Rule 10b5-1 trading plan adopted on December 27, 2023.
• Following these sales, Young directly owns 263,306 shares of Akero Therapeutics common stock.
• Young also has indirect ownership of 60,000 shares held in irrevocable trusts for the benefit of his children.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-arranged trading plan. There's no indication of positive or negative sentiment towards the company's prospects.

Industry Context

Insider trading activity is always closely watched by investors as it can provide signals, though often noisy, about management's view of the company's prospects. In this case, the sales were conducted under a pre-arranged 10b5-1 trading plan, which is designed to allow insiders to sell shares without being accused of trading on non-public information.

Stakeholder Impact

• The stock sale may have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates